QIAGEN announces CE marking of T-cell response measuring device
December 2, 2021Business Services
QIAGEN has launched a CE-marked version of its QuantiFEROn SARS-CoV-2 assay, which measures T-cell responses to SARS-CoV-2, and aids in …
UK regulator approves antibody drug which may help tackle Omicron
December 2, 2021Research and Development
UK drug regulators have approved Xevudy (sotrovimab), a new coronavirus antibody treatment made by GlaxoSmithKline (GSK), which has been found …
EU bring forward launch of COVID-19 vaccine for children
December 1, 2021Research and Development
The rollout of Pfizer and BioNTech’s COVID-19 vaccine version for children aged five to 11 years old will begin on …
UK Health Secretary Javid urges for more COVID-19 tests amid rising Omicron cases and vaccine developments
December 1, 2021Research and Development
Health secretary of the UK, Sajid Javid, has urged the public to take lateral flow tests before attending parties this …
FDA approves new drug for identification of ovarian cancer
November 30, 2021Manufacturing and Production
The FDA announced the approval of pafolacianine, marketed as Cytalux, a new drug which could help doctors detect ovarian cancer …
FDA plans fast approvals for Omicron-targeting vaccines
November 30, 2021Manufacturing and Production
Joe Biden has directed the FDA and CDC to respond quickly to applications for vaccines or boosters to shield against …
NICE recommends Tagrisso (osimertinib) in England for lung cancer patients
November 30, 2021Manufacturing and Production
AstraZeneca have announced that Tagrisso (osimertinib) is now available as an adjuvant treatment option to patients in England with completely …
Vaccine makers pledge to develop Omicron-effective jab
November 29, 2021Sales and Marketing
Leading vaccine producers have shared that they are already pursuing vaccine responses to the newly-discovered coronavirus variant, Omicron. BioNTech has …
Nottinghamshire school sets up targeted testing for Omicron
November 29, 2021Sales and Marketing
A school in Nottingham has set up targeted testing after a case of the new COVID-19 variant, Omicron, was detected …
WHO: unclear if Omicron causes severe disease
November 29, 2021Sales and Marketing
WHO has shared that it is still unclear whether the recently-detected coronavirus variant Omicron is more transmissible, or causes more …
FDA approves AI-based breast cancer screening software MammoScreen®
November 29, 2021Sales and Marketing
The FDA has approved MammoScreen®, Therapixel’s explainable and actionable Artificial Intelligence (AI) based software assisting Radiologists in breast cancer screening. …
New COVID-19 variant in South Africa as massive surge in Europe infections
November 26, 2021Medical Communications
A new variant of coronavirus found in South Africa is feared to be more transmissible than other strains, and poses …
Allorion gains $40 million funding to enhance and discover precision targets
November 26, 2021Medical Communications
Allorion Therapeutics has announced that they have gained $40 million in Series A financing. The funding was led by Chinese …
US government expands COVID-19 booster eligibility ahead of holidays
November 25, 2021Business Services
The Biden administration has expanded COVID-19 booster eligibility, and millions of Americans have received their booster shots at a near …
Groundbreaking success shown in target drug combination for aggressive brain tumours
November 25, 2021Business Services
A combination of two targeted cancer drugs have shown unprecedented activity in patients with highly malignant brain tumours carrying a …
FDA approve first therapy to treat ultra-rare cancer
November 24, 2021Research and Development
Aadi Bioscience announced that the FDA have approved the intravenous drug Fyarro (sirolimus protein-bound particles for injectable suspension) for the …
Ocuphire announces beginning of Phase III trial of treatment for reversal of mydriasis (RM)
November 24, 2021Research and Development
Ocuphire Pharma, a clinical-stage ophthalmic biopharmaceutical company, announced that the first subjects have been enrolled in the MIRA-3 Phase III …
FDA approves Livtencity as first treatment for drug-resistant post-transplant infection
November 24, 2021Manufacturing and Production, Research and Development
The FDA have approved Livtencity (maribavir) as the first drug for treating adults and pediatric patients with a common type …
HUTCHMED and AstraZeneca begin Phase III trial of lung cancer treatment
November 24, 2021Research and Development
HUTCHMED Limited and AstraZeneca have initiated SACHI, a China Phase III study of Savolitinib (ORPATHYS®), an oral, potent, and highly …
Santhera and ReveraGen announce positive results from VISION-DMD study
November 23, 2021Manufacturing and Production
Santhera Pharmaceuticals and ReveraGen BioPharma have announced new topline results after completion of the VISION-DMD study at week 48.
Latest content
